ArticleCJC open2025
Implications of Inaccurate Blood Pressure Measurement on Hypertension Prevalence.
Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The cornerstone of the management of hypertension is accurate measurement of blood pressure (BP). A recent study showed that more than one-half of home BP devices sold in Canada have no evidence of validation for accuracy. The purpose of this study was to model the implications of inaccurate BP measurements on diagnosis and control of hypertension. Methods: We used data from the Canadian Health Measures Survey to model the effects of inaccurate BP devices by 5 or 10 mm Hg over or under the true BP value. Hypertension was defined as BP ≥ 140/90 mm Hg (or ≥130/80 mm Hg in those patients with diabetes). Results: If both systolic and diastolic BP were overestimated by 10 mm Hg, the prevalence of hypertension would falsely increase by 50% to 63%, potentially leading to overtreatment of approximately 3.5 million Canadians. Conversely, the impact of underestimation of BP appeared minimal, but mostly because of design limitations of our study. Conclusions: We found that overestimation of BP by only 10 mm Hg could lead to overtreatment of up to 3.5 million Canadians. Government should mandate the validation of BP devices before they can be sold; until then, clinicians and patients should be cautious in their selection of BP devices, using the Hypertension Canada Recommended Device Program to guide selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.